CHAMPIONS ONCOLOGY•Financial Summary•AI-Powered Insights

CHAMPIONS ONCOLOGY 2026 Q2
Earnings Overview & AI Insights

Detailed performance report for CHAMPIONS ONCOLOGY covering Q2 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

CHAMPIONS ONCOLOGY (2026 Q2)

Earnings Performance

No Performance Data

Summary of Financial Performance:
Champions Oncology reported Q1 fiscal 2027 revenue of $15.2 million, up about 9% year over year from $14.0 million. Gross margin expanded to 50% from 43%, driven by improved oncology services margins, lower third-party radiolabeling costs, and operating leverage. Adjusted EBITDA was $671,000 to $700,000, marking the fifth consecutive quarter of positive adjusted EBITDA. GAAP net loss was approximately $426,000, versus a $527,000 operating loss in the prior-year quarter, and the company ended with $4.4 million in cash and no debt.

Company Outlook & Strategy:
Management said fiscal 2026 was an investment year and Q1 fiscal 2027 shows those investments are beginning to convert into revenue, margin expansion, and improved profitability. The company emphasized continued growth in both its services and data businesses, with a focus on converting contracted study value into revenue and expanding profitability. Leadership also noted that if Corellia secures outside funding or a partnership, capital currently allocated there could be redirected toward other growth initiatives, especially data and the bottom line.

Key Industry Trends:
The company highlighted healthy demand for translational oncology services and a strong market need for deeply characterized, clinically annotated, patient-derived data. Management said AI and machine learning are increasingly central to drug development, but the limiting factor is high-quality underlying data, which they believe Champions has a differentiated position to provide. The broader trend is toward better patient selection, biomarker discovery, and improved trial design.

Operational Highlights:
Translational oncology services revenue was $14.3 million, with margin holding at desired levels and benefit from operating discipline. Data licensing revenue was $893,000, exceeding all of fiscal 2026 in just one quarter, though management said this revenue stream will remain lumpy due to contract timing. The company improved cost efficiency by bringing radiolabeling capabilities in-house, reducing revenue costs by about $500,000. R&D spending declined to $1.9 million as resources were redirected toward Corellia and data initiatives, while sales and marketing rose to $3.0 million due to prior commercial team expansion.

Challenges & Risks:
Management reiterated that data licensing revenues will remain uneven quarter to quarter because contracts close on different timelines. Corellia remains a source of uncertainty, with no timeline given for external funding or a partnership. The company also noted higher accounts receivable and lower accounts payable as working-capital uses of cash during the quarter. Broader execution risk remains centered on sustaining revenue conversion, maintaining expense discipline, and proving the durability of recent margin gains.

Key Analyst Questions & Responses:
There was no Q&A session; the company reported that no questions were in the queue.

Earnings Call Transcript

Access the official earnings call transcript for CHAMPIONS-ONCOLOGY 2026 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.